Millinette (Ethinylestradiol, Gestodene)

Ethinylestradiol / Gestodene, the active ingredient in Millinette, is a combined oral contraceptive presented as 30 µg ethinylestradiol / 0.075 mg gestodene oral tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Millinette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing regulatory documentation for global distribution.

Millinette, a combined oral contraceptive, is used within the hormonal regulation pathway to prevent unintended pregnancy.

- Prevention of pregnancy: provides reliable contraception for women of reproductive age. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns. - Management of dysmenorrhea: reduces menstrual pain associated with ovulatory cycles.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: transient swelling or soreness. - Spotting between periods: occasional light bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hypertensive disorders: significant increase in blood pressure. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Millinette, clinicians should consider the following precautions: - Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used by pregnant women. - Avoid in smokers over 35 years: smoking markedly raises cardiovascular risk. - History of thromboembolism: contraindicated in women with prior VTE or clotting disorders. - Monitor blood pressure: the formulation may elevate systolic or diastolic values. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Millinette may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): markedly reduce contraceptive efficacy. - Rifampicin: decreases plasma hormone levels, increasing risk of contraceptive failure. - Protease inhibitors (e.g., ritonavir): may raise hormone exposure and heighten adverse‑event risk.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., tetracycline): can slightly lower contraceptive effectiveness. - St. John’s wort: may reduce hormone concentrations. - Diuretics (e.g., spironolactone): can augment the risk of hypertension while on the pill.